Zia; Vahid

Patent Applications and Registrations

Patent applications and USPTO patent grants for Zia; Vahid.The latest application filed is for "combination formulation of two antiviral compounds".

Company Profile

7.22.36

Zia; Vahid - Palo Alto CA
Zia; Vahid - San Carlos CA
Zia; Vahid - Foster City CA
Zia; Vahid - San Francisco CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Combination Formulation Of Two Antiviral Compounds App 20220072021 - Gorman; Eric ; et al.	2022-03-10
Crystalline forms of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13- ,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-1- 0-carboxamide Grant 11,202,780 - Carra , et al. December 21, 2	2021-12-21
Combination formulation of two antiviral compounds Grant 11,116,783 - Gorman , et al. September 14, 2	2021-09-14
Combination Formulation Of Two Antiviral Compounds App 20210000854 - Gorman; Eric ; et al.	2021-01-07
Crystalline Forms Of (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13- ,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-1- 0-carboxamide App 20200390775 - Carra; Ernest A. ; et al.	2020-12-17
Compositions and methods of treating HIV Grant 10,786,518 - Boven , et al. September 29, 2	2020-09-29
Combination Formulation Of Two Antiviral Compounds App 20200188419 - Chal; Ben ; et al.	2020-06-18
Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,- 5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxa- zepin-8-olate Grant 10,385,067 - Carra , et al. A	2019-08-20
Combination Formulation Of Two Antiviral Compounds App 20190240246 - Gorman; Eric ; et al.	2019-08-08
Combination Formulation Of Two Antiviral Compounds App 20190111068 - Chal; Ben ; et al.	2019-04-18
Compositions and Methods of Treating HIV App 20190022113 - Boven; Katia ; et al.	2019-01-24
Crystalline Forms Of (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13- ,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-1- 0-carboxamide App 20190015420 - Carra; Ernest A. ; et al.	2019-01-17
Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13- ,13A- octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-B] [1,3] oxazepine-10-carboxamide Grant 10,098,886 - Carra , et al. October 16, 2	2018-10-16
Combination formulation of two antiviral compounds Grant 10,086,011 - Gorman , et al. October 2, 2	2018-10-02
Combination formulation of two antiviral compounds Grant 10,039,779 - Chal , et al. August 7, 2	2018-08-07
Sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,- 5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxa- Zepin-8-olate App 20180065986 - CARRA; ERNEST A. ; et al.	2018-03-08
Combination Formulation Of Two Antiviral Compounds App 20180021362 - Gorman; Eric ; et al.	2018-01-25
Compositions And Methods For Treating Hepatitis C Virus App 20170348342 - Berrey; Miriam Michelle ; et al.	2017-12-07
Crystalline Forms Of (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13- ,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-1- 0-carboxamide App 20170333438 - Carra; Ernest A. ; et al.	2017-11-23
Combination formulation of two antiviral compounds Grant 9,757,406 - Gorman , et al. September 12, 2	2017-09-12
Combination Formulation Of Two Antiviral Compounds App 20170202865 - Chal; Ben ; et al.	2017-07-20
Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,- 5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate Grant 9,708,342 - Carra , et al. July 18, 2	2017-07-18
Sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,- 5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxa- Zepin-8-olate App 20170197985 - Carra; Ernest A. ; et al.	2017-07-13
Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9,-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,1- 3,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-- 10-carboxamide Grant 9,682,084 - Carra , et al. June 20, 2	2017-06-20
Combination Formulation Of Two Antiviral Compounds App 20170095499 - Gorman; Eric ; et al.	2017-04-06
Compositions and methods for treating hepatitis C virus Grant 9,549,941 - Cleary , et al. January 24, 2	2017-01-24
Solid forms of an antiviral compound Grant 9,340,568 - Casteel , et al. May 17, 2	2016-05-17
Combination Formulation Of Two Antiviral Compounds App 20160120892 - Chal; Ben ; et al.	2016-05-05
Sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,- 5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b]oxazepin- -8-olate App 20160016973 - Carra; Ernest A. ; et al.	2016-01-21
Crystalline Forms Of (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13- ,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-1- 0-carboxamide App 20150366872 - Carra; Ernest A. ; et al.	2015-12-24
Solid Forms Of An Antiviral Compound App 20150175646 - Casteel; Melissa Jean ; et al.	2015-06-25
Compositions And Methods For Treating Hepatitis C Virus App 20150150896 - Cleary; Darryl G. ; et al.	2015-06-04
Combination Formulation Of Two Antiviral Compounds App 20150064253 - Gorman; Eric ; et al.	2015-03-05
Solid Dispersion Formulation Of An Antiviral Compound App 20150064252 - Gorman; Eric ; et al.	2015-03-05
Compositions and methods for treating hepatitis C virus Grant 8,889,159 - Cleary , et al. November 18, 2	2014-11-18
Combination Formulation Of Two Antiviral Compounds App 20140212491 - Chal; Ben ; et al.	2014-07-31
Solid Dispersion Formulation Of An Antiviral Compound App 20140212487 - Mogalian; Erik ; et al.	2014-07-31
Pyridazine compound and use thereof Grant 8,569,487 - Bondy , et al. October 29, 2	2013-10-29
Crystalline pyridazine compound Grant 8,569,488 - Dowdy , et al. October 29, 2	2013-10-29
Compositions And Methods For Treating Hepatitis C Virus App 20130136776 - Cleary; Darryl G. ; et al.	2013-05-30
Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment Grant 8,329,727 - Bondy , et al. December 11, 2	2012-12-11
Crystalline Pyridazine Compound App 20120108601 - Dowdy; Eric D. ; et al.	2012-05-03
Crystalline pyridazine compound Grant 8,106,054 - Dowdy , et al. January 31, 2	2012-01-31
S-[2-[(1-iminoethy)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride crystalline salt Grant 7,767,850 - Brostrom , et al. August 3, 2	2010-08-03
Pyridazine compound and use thereof Grant 7,754,720 - Bondy , et al. July 13, 2	2010-07-13
Novel Pyridazine Compound And Use Thereof App 20100152444 - Bondy; Steven S. ; et al.	2010-06-17
Novel Pyridazine Compound And Use Thereof App 20100063059 - Bondy; Steven S. ; et al.	2010-03-11
IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT App 20100028301 - Bondy; Steven S. ; et al.	2010-02-04
Imidazo 4,5-c pyridine compounds and methods of antiviral treatment Grant 7,648,998 - Bondy , et al. January 19, 2	2010-01-19
S-[2-[(1-lminoethy)Amino]Ethyl]-2-Methyl-L-Cysteine Maleate Hydrochloride Crystalline Salt App 20090215891 - Brostrom; Lyle ; et al.	2009-08-27
Crystalline pyridazine compound App 20090036460 - Dowdy; Eric D. ; et al.	2009-02-05
Novel pyridazine compound and use thereof App 20080199427 - Bondy; Steven S. ; et al.	2008-08-21
Processes and intermediates useful for preparing integrase inhibitor compounds App 20080039487 - Evans; Jared W. ; et al.	2008-02-14
Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment App 20070244148 - Bondy; Steven S. ; et al.	2007-10-18
Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment App 20050222198 - Bondy, Steven S. ; et al.	2005-10-06
S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride crystalline salt App 20050038120 - Brostrom, Lyle ; et al.	2005-02-17

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.